Cognitive-behaviour therapy and schizophrenia

Til Wykes

Institute of Psychiatry, King’s College London, London, UK
Correspondence to Til Wykes, t.wykes@kcl.ac.uk

ABSTRACT
People who experience debilitating psychotic symptoms that affect their everyday life are often, but not always, given a diagnosis of schizophrenia. Although the first line of treatment is medication, many people experience a suboptimal response and after the acute symptoms resolve they can continue to experience both hallucinations and delusions. These are generally termed residual symptoms and are the phenomena that cognitive-behavioural therapy for psychosis (CBTp) was originally devised to target. The success of CBTp in randomised controlled trials from the early 90s and evidence of cost-effectiveness has meant that many healthcare services across the world include CBTp in their treatment armamentaria. For instance, in the UK the National Institute for Health and Care Excellence guidance says that all individuals who have a diagnosis of schizophrenia should be given the option of a course of CBTp. Recently, however, the treatment effects have been re-examined, the targets widened and the premise that CBTp should be solely an adjunct to medication has been questioned. This article will describe and probe some of these changes and reflect on the development of psychological treatments for psychosis.

WHAT IS COGNITIVE-BEHAVIOURAL THERAPY FOR PSYCHOSIS?
As cognitive-behavioural therapy for psychosis (CBTp) expands to address other targets, it is important to consider its origins and vital ingredients.
CBTp is a verbal therapy to ease distress by reducing positive symptoms. It does this by mobilising the client’s capacity to reflect on and to question delusional or self-evaluative beliefs through a ‘collaborative empirical’ enterprise. The therapist joins forces with the client to question beliefs that limit the achievement of personal life goals. The journey through therapy (usually 20 or so sessions over 6–9 months) allows for the collaborative development of an understanding of distressing psychotic experiences. The clients are then guided to re-evaluate their appraisals of experiences and identify new ways of responding to them. Towards the end of therapy further collaborative work on maintaining factors is carried out to support the individual to prevent relapse. Usually this involves issues such as reasoning style, self-concept, social isolation, appraisals of psychosis and emotional processes. Models are provided for therapy development and all therapists are expected to cultivate a shared formulation of the relationship between the experiences, the thoughts and the problematic behaviour. In this paragraph I have tried to describe what in many books takes more than 300 pages and usually months of therapy training to achieve delivery competence (although the level of skills required is debated). The introduction of this therapy was a turning point in mental health-effects. Different groups, we may be more certain that the results are true effects.

THERAPY EFFECTIVENESS
The gauge of therapy effectiveness is usually a meta-analysis. These studies follow rules now described in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines which require authors to specify their inclusion criteria (therapy description, participants and target outcomes), data extraction, data quality checks, etc. Although following these rules allows for robust replication, it is still important that the research team has access to therapeutic expertise in order to detect true trials of the therapy under investigation. All meta-analyses also depend on the level of development of the therapy so that early in development there will be more pilot or exploratory trials that may be open to bias. However, after multiple replications by different groups, we may be more certain that the results are true effects.

One meta-analysis carried out a strict investigation of CBTp with 25 trials of the effects on one outcome—positive symptoms—which was the target designated for the original development of CBTp. This meta-analysis also reported on the overall effects after considering those studies with a high likelihood of bias using a scale formatted specifically for psychological treatment trials. As might be expected, the effect size from trials with a low risk of bias was smaller than that for studies with a high risk, but it was still significant. This same meta-analysis also demonstrated that individual assessors being blind to the treatment allocation was the most significant predictor of the bias. This is not a new finding and has been reported for treatments in many other disorders and for other treatments such as medication. So this might be thought of as a slam dunk and we do not need to do any more, but recently a series of meta-analyses were produced investigating current data and testing both the expansion of CBTp to targets other than positive symptoms as well as comparing CBTp with other treatments.

CBTp has expanded to include targets such as negative symptoms, social outcomes and compliance with command hallucinations, among many others. The formulation-based approach which is a high-light of this therapy has led to subtle adaptations which allow a clear movement towards these target-based goals. This, of course, leads to outcomes that are tailored and are usually not measured as traditional positive symptoms and the trials are powered for these new outcomes. It is therefore vital to ensure that in any meta-analysis the right outcomes are compared. The ‘washing machine’ approach of meta-analyses throwing together studies targeting differing outcomes but measuring the same one can produce some interesting data on effectiveness. If it is positive, then this suggests that all CBTs can affect a variety of outcomes (the target and others), but if effectiveness is not equivalent for all outcomes and possibly a tailored approach would be more effective. Luckily the recent published meta-analyses can throw some light on these effects. All are rigorous and are carried out according to the PRISMA guidance and all include sensitivity to the likelihood of bias resulting from poorer methods.

THE STORY SO FAR...
This year Jauhar et al included a wide variety of studies—34 in all. This meta-analysis emphasised the overall value of CBTp approaches to both positive and negative symptoms derived from assessor interviews. However, the inclusion criteria did exclude some targeted therapies, in particular those that targeted hallucinations. In their analyses they
discovered a benefit of CBTp across all studies but when they considered only those with blinded assessment the CI crossed zero. Burns et al. also collated studies with all targets but specified a further inclusion criterion—positive symptoms that were medication resistant. They found a benefit (effect size = 0.43; 95% CI 0.20 to 0.67) for studies with blinded group allocation. So what are we to make of the different results? Clearly with a specific group—those with medication resistant symptoms—we can reasonably assume that there is a modest effect and this is understandable as this was the original remit for the development of CBTp. The study by van der Gaag et al. supports this conclusion as their meta-analysis disaggregated delusions and hallucinations as outcomes and found a benefit of CBTp to both targets even after taking into account blinded assessment. So therapy benefits may be dependent on the specific target, how these are measured and the types of individuals included in the studies.

IS CBTP DIFFERENT FROM ANY OTHER PSYCHOLOGICAL TREATMENT?

This is an important question as it affects treatment guidance in general and the necessity for training for more complex therapies. It is answered in a paper comparing psychological treatments such as social skills, cognitive remediation, CBTP, befriending, psychoeducation and supportive counselling. In the set of studies with a low risk of bias, CBTP was the most effective for positive symptoms (effect size = 0.16) compared to all other treatments. So there are differences in efficacy of psychological treatments for psychosis which can guide treatment choice which should depend on what individual patients select as their main goal. Differences in effectiveness found in this meta-analysis are consistent with the specific factors in the interventions and their specific targets in particular.

IS CBTP STANDING STILL?

Two further meta-analyses published in the past year suggest even more ambitious targets. These meta-analyses investigated the potential of CBTP to prevent psychosis when an individual begins to experience symptoms. Van der Gaag et al. demonstrated that for CBTP-based interventions there is reduced transition to psychosis (relative risk = 0.52) with a number needed-to-treat (NNT) of 13 (95% CI 7 to 71) at 12 months; Hutton and Taylor found less transition at 6, 12 and 18 months, with an NNT of 20. The new National Institute for Health and Care Excellence (NICE) guidelines also suggest using CBTP as the first-line treatment in at-risk groups. CBTP is still rapidly moving forward. We now have combination treatments to get maximal effects (eg, motivational interviewing; cognitive remediation) and also the inclusion of new groups of individuals. For instance in a paradigm changing study for people with continuing symptoms but who refuse medication, Morrison et al. demonstrated successful treatment by CBTP. This is the first time such an RCT has been carried out and the authors are to be commended on their rigour and particularly on reporting adverse events (2 in the CBTP group vs 6 in the control group). The study challenges the belief that CBTP is only an adjunct to medication treatment in more chronic populations—although we cannot yet conclude that CBTP should be recommended until we have more and larger trials.

SO IS CBTP EFFECTIVE?

All the meta-analyses described here were carried out rigorously. They allow us to draw a picture of a therapy that developed from its roots in medication-resistant positive symptoms to the wealth of new targets and then to the more radical—the prevention of psychosis. Only one recent meta-analysis does not show beneficial effects after accounting for methodology. This odd one out is odd for very good reasons and provides us with a backdrop to understand the treatments required in the future. We cannot now consider CBTP as one global brand. Not all CBTPs are the same. They differ in their models, the length of treatment, their targets and, probably importantly, the types of individuals who can benefit from therapy. One recommendation based on this corpus of data is that treatment allocation should take into account patient defined goals and critical targets that limit recovery in choosing the most appropriate CBTPs from the current recipe book.

Acknowledgements

Til Wykes would like to acknowledge the support of the NIHR BRC in mental health at the South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, KCL. She would also like to acknowledge her NIHR Senior Investigator Award.

Competing interests

None.

REFERENCES

Cognitive-behaviour therapy and schizophrenia

Til Wykes

*Evid Based Mental Health* 2014 17: 67-68
doi: 10.1136/eb-2014-101887

Updated information and services can be found at:
http://ebmh.bmj.com/content/17/3/67

**References**

This article cites 16 articles, 4 of which you can access for free at:
http://ebmh.bmj.com/content/17/3/67#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- **Editor's choice** (89)
- **Schizophrenia spectrum** (429)
- **Neurology** (1067)

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/